Can adjuvant chemoradiotherapy replace extended lymph node dissection in gastric cancer?

Area of Science:

• Surgical Oncology
• Gastrointestinal Oncology
• Radiation Oncology

Background:

• Surgical resection is key for gastric cancer cure, but long-term survival with surgery alone is poor.
• Western randomized trials comparing D1 and D2 lymph node dissection have not shown survival benefits for more extensive surgery.
• Perioperative chemotherapy (MAGIC study) and postoperative chemoradiotherapy (CRT) (SWOG/Intergroup 0116) have shown survival benefits.

Purpose of the Study:

• To evaluate the effectiveness of adjuvant chemoradiotherapy (CRT) in resected gastric cancer patients.
• To compare outcomes of patients treated with CRT versus surgery alone.
• To determine if optimal D2 gastric surgery requires postoperative CRT for improved survival.

Main Methods:

• Phase I-II studies of adjuvant cisplatin and capecitabine-based CRT in over 120 resected gastric cancer patients.
• Retrospective comparison with patients from the D1D2 study who had surgery only.
• Ongoing prospective randomized phase III trials (CRITICS; TOPGEAR) are testing CRT after D2 resection.

Main Results:

• Retrospective analysis suggests postoperative CRT improves outcomes, especially after D1 or R1 resection.
• A Korean study indicated better outcomes with postoperative CRT after D2 dissection in advanced gastric cancer.
• Evidence suggests CRT may enhance survival in specific surgical contexts.

Conclusions:

• Postoperative CRT appears beneficial for gastric cancer patients, particularly those with less optimal surgical resection (D1 or R1).
• The benefit of postoperative CRT after optimal D2 gastric surgery remains uncertain.
• Prospective trials are crucial to definitively establish the role of CRT in optimizing survival after gastric cancer surgery.